Want to see CH:PPGN full AI Analyst Report?
Top Page
PolyPeptide Group AG
(PPGN)
Select Model
Select Model
Rating:56Neutral
Price Target:
CHF51.00
▲(71.14% Upside)
Action:Reiterated
Date:07/04/26
The score is held back mainly by weak financial performance (continued net losses and volatile free cash flow) and unattractive earnings-based valuation (negative P/E). These are partly offset by strong technical momentum with price well above key moving averages, though overbought indicators add near-term risk.
Positive Factors
CDMO specialization & multi-site GMP capacity
A focused CDMO model for peptides/oligonucleotides with multi-site GMP manufacturing is a durable competitive strength. It supports long-term contract wins, scale-up continuity, and regulatory compliance, enabling recurring commercial-supply revenues and higher switching costs for customers.
Negative Factors
Persistent net losses
Sustained net losses across multiple years erode retained earnings and constrain the company's ability to self-fund growth. Over months to quarters this limits free capital for strategic investments, raises the likelihood of external financing or dilution, and weighs on long-term return generation.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO specialization & multi-site GMP capacity
A focused CDMO model for peptides/oligonucleotides with multi-site GMP manufacturing is a durable competitive strength. It supports long-term contract wins, scale-up continuity, and regulatory compliance, enabling recurring commercial-supply revenues and higher switching costs for customers.
Read all positive factors
PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF1.52B
Dividend YieldN/A
Average Volume (3M)34.07K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth13.85%
EPS Growth-7.03%
CountryCH
Employees1,440
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.50Price Target Upside35.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)CHF490.04M
PolyPeptide Group AG Business Overview & Revenue Model
Company Description
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic f...
How the Company Makes Money
PolyPeptide Group makes money primarily by providing contract development and manufacturing services to pharmaceutical and biotechnology customers that need peptide (and, where applicable, oligonucleotide) APIs for clinical and commercial drug pro...
PolyPeptide Group AG Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
51
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 391.87M | 338.69M | 320.37M | 280.98M | 282.13M |
| Gross Profit | 64.32M | 39.27M | 4.77M | 51.99M | 99.70M |
| EBITDA | 44.42M | 28.42M | -22.15M | 35.72M | 83.35M |
| Net Income | -21.31M | -19.56M | -51.44M | 7.77M | 47.26M |
Balance Sheet | |||||
| Total Assets | 825.31M | 756.58M | 689.09M | 575.78M | 595.04M |
| Cash, Cash Equivalents and Short-Term Investments | 74.53M | 68.28M | 95.71M | 37.53M | 136.30M |
| Total Debt | 130.46M | 94.12M | 113.66M | 21.22M | 18.00M |
| Total Liabilities | 484.98M | 399.33M | 307.86M | 154.10M | 173.87M |
| Stockholders Equity | 340.33M | 357.24M | 381.23M | 421.68M | 421.17M |
Cash Flow | |||||
| Free Cash Flow | -30.44M | 2.43M | -20.25M | -69.64M | -16.61M |
| Operating Cash Flow | 78.02M | 89.40M | 36.48M | 5.46M | 57.35M |
| Investing Cash Flow | -112.44M | -91.02M | -59.51M | -78.44M | -80.84M |
| Financing Cash Flow | 34.01M | -25.32M | 84.55M | -26.87M | 130.93M |
PolyPeptide Group AG Technical Analysis
Positive
29.80
Price Trends
40.10
Positive
34.44
Positive
30.02
Positive
Market Momentum
2.44
Positive
58.64
Neutral
23.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Positive. The current price of 29.8 is below the 20-day moving average (MA) of 43.98, below the 50-day MA of 40.10, and below the 200-day MA of 30.02, indicating a bullish trend. The MACD of 2.44 indicates Positive momentum. The RSI at 58.64 is Neutral, neither overbought nor oversold. The STOCH value of 23.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:PPGN.
PolyPeptide Group AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF5.61B | 37.39 | 9.76% | 1.43% | 14.84% | 23.77% | |
66 Neutral | CHF29.82B | 38.38 | 2.64% | 1.02% | 0.80% | 28043.55% | |
63 Neutral | CHF40.59B | 77.82 | ― | 0.09% | 11.15% | 150.71% | |
62 Neutral | CHF3.27B | 18.95 | 15.79% | 0.51% | 2.57% | 4.31% | |
56 Neutral | CHF1.52B | -76.95 | ― | ― | 13.85% | -7.03% | |
56 Neutral | CHF39.93B | -150.15 | ― | 0.75% | -0.65% | -143.04% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:PPGN
PolyPeptide Group AG
47.20
25.50
117.51%
CH:LONN
Lonza Group Ltd
582.40
24.65
4.42%
CH:BANB
Bachem Holding AG
75.40
19.13
33.98%
CH:SFZN
Siegfried Holding AG
73.05
-15.70
-17.69%
CH:SDZ
Sandoz Group Ltd
65.18
20.26
45.09%
CH:GALD
Galderma Group AG
168.75
43.42
34.65%
PolyPeptide Group AG Corporate Events
PolyPeptide Confirms Strategic Review Amid Takeover Speculation
Apr 14, 2026
PolyPeptide Group AG, a global CDMO for peptide-based active pharmaceutical ingredients, supports customers from pre-clinical to commercial stages across a broad portfolio, particularly in metabolic diseases. The Swiss-listed company operates a ne...
PolyPeptide shareholders back all proposals at 2026 AGM
Apr 8, 2026
Shareholders of PolyPeptide Group AG approved all board proposals at the company’s fifth ordinary Annual General Meeting, with 26,780,855 voting shares represented, or 80.85% of the issued share capital. The strong turnout underscores solid ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.